(Q37357924)

19 August 2017

1 reference

title

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1

Gabriella Mariani

1 reference

19 August 2017

4

Luca Gianni

1 reference

19 August 2017

Angelica Fasolo

2

1 reference

PubMed ID

19107109

19 August 2017

Elena De Benedictis

series ordinal

3

1 reference

19 August 2017

23 December 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

1 reference

19 August 2017

6

1 reference

19 August 2017

93-104

1 reference

19 August 2017

2

1 reference

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

19 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1298

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1298

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1298

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

12 December 2020

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

12 December 2020

The cost of life: should it matter to doctors?

1 reference

12 December 2020

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

12 December 2020

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

1 reference

12 December 2020

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

12 December 2020

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

12 December 2020

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

1 reference

12 December 2020

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

1 reference

12 December 2020

EGF-ERBB signalling: towards the systems level

1 reference

12 December 2020

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

12 December 2020

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Trastuzumab in the treatment of breast cancer

1 reference

12 December 2020

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

1 reference

12 December 2020

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

12 December 2020

TEACH: Tykerb evaluation after chemotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

12 December 2020

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

12 December 2020

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

12 December 2020

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

12 December 2020

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

12 December 2020

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

12 December 2020

Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

1 reference

12 December 2020

Herceptin and the heart--a molecular modifier of cardiac failure

1 reference

12 December 2020

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Dose scheduling--Herceptin

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

12 December 2020

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

12 December 2020

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

1 reference

12 December 2020

Lapatinib: current status and future directions in breast cancer

1 reference

12 December 2020

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

12 December 2020

Clinical cardiac tolerability of trastuzumab

1 reference

12 December 2020

Resistance to trastuzumab: a necessary evil or a temporary challenge?

1 reference

12 December 2020

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

1 reference

12 December 2020

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1298

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NCPONC1298

1 reference

19 August 2017

1 reference

PubMed ID

19107109